
Zoetis Inc. (ZTS) – Robust global growth
in Company Report , Healthcare & Life Sciences , Pharma & Biotech on October 11, 2023Zoetis Inc. (ZTS) (Q2FY23)
Stock Performance – Zoetis stock price showed a volatile trend in the past 3 months. It gave 0.06% return during the period. The stock price increased by 10.07% in past 1-year. The stock has a 52-week high of $194.99 and its 52-week low is $124.15.
In the past 3 years, the stock has given returns of 4.15%. ZTS has a 50-day moving Avg. and 200-day moving Avg. of $182.91 and $171.71, respectively.
Revenue Performance – ZTS reported revenue of $2.2bn for Q2FY23, an increase of 6% compared with the second quarter of 2022.On an operational basis, revenue for the second quarter of 2023 increased 9% compared with the second quarter of 2022,
excluding the impact of foreign currency.
Company Guidance for FY23 – ZTS expect revenue to between $8.500bn to $8.650bn. Reported net income is expected to be between $2.400bn to $2.460bn.
Highlights
The company experienced significant growth in its companion animal segment, marked by an impressive 11% operational revenue increase. The company’s dermatology products played a crucial role in driving revenue growth within the companion animal segment. These products likely addressed various skin-related issues in pets, contributing to increased sales.
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
No of Pages: 35
To download the previous quarter’s equity/report CLICK HERE
To Download other equity/reports CLICK HERE
Follow our LinkedIn page for more updates.